SELF will always acknowledge that “obesity” is both a flawed metric of health and a stigmatizing term. SELF will only talk ...

Drugs like Ozempic and Wegovy have the power to block the forces driving obesity, but the knock-on societal effects may not ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) while Ozempic (Semaglutide) only targets GLP-1.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Men's big-and-tall retailer DXL is expecting, perhaps ironically, to benefit from the popularity of GLP-1 drugs such as ...

While anecdotal evidence suggests those taking the type 2 diabetes drug with a side effect of weight loss may lead to hair ...

Mounjaro, Eli Lilly's diabetes and obesity drug, is now available in India at a fraction of its US price. It offers treatment for weight loss and diabetes control, but watch out for the side effects ...

For months, there have been rumblings online about Ozempic being linked to hair loss. But like Ozempic face, Ozempic butt, ...